Rage signalling promotes intestinal tumourigenesis

Oncogene

Volumn 32, Issue 9, 2013, Pages 1202-1206

  Heijmans, J ^a,b   Buller N V J A ^a,b   Hoff, E ^b   Dihal, A A ^b   Van Der Poll, T ^a   Van Zoelen, M A D ^a   Bierhaus, A ^c   Biemond, I ^b   Hardwick, J C H ^b   Hommes, D W ^b   Muncan, V ^a,b   Van Den Brink, G R ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

ApcMin; intestinal adenoma; MyD88; Rage

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; HOMOZYGOSITY; INTESTINE POLYP; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOMA; ANIMALS; INTESTINAL NEOPLASMS; MICE; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION;

MUS;

EID: 84874691073     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.119     Document Type: Article

References (26)

1. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-296.
2. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007; 317: 124-127.
3. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 1228-1233.
4. Ekbom A, Helmick C, Zack M, Adami HO. Increased risk of large-bowel cancer in Crohn0s disease with colonic involvement. Lancet 1990; 336: 357-359.
5. Neufert C, Becker C, Neurath MF. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc 2007; 2: 1998-2004.
6. Fukata M, Shang L, Santaolalla R, Sotolongo J, Pastorini C, Espana C et al. Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis 2011; 17: 1464-1473.
7. Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008; 29: 2035-2043.
8. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001; 1: 135-145.
9. van Zoelen MA, Achouiti A, van der Poll T. The role of receptor for advanced glycation endproducts (RAGE) in infection. Crit Care 2011; 15: 208.
10. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331-342.
11. He M, Kubo H, Morimoto K, Fujino N, Suzuki T, Takahasi T et al. Receptor for advanced glycation end products binds to phosphatidylserine and assists in the clearance of apoptotic cells. EMBO Rep 2011; 12: 358-364.
12. Du YS, Zhu H, Fu J, Yan SF, Roher A, Tourtellotte WW et al. Amyloid-beta peptidereceptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA 1997; 94: 5296-5301.
13. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-759.
14. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990; 247: 322-324.
15. Lee SH, Hu LL, Gonzalez-Navajas J, Seo GS, Shen C, Brick J et al. ERK activation drives intestinal tumorigenesis in Apc(min/+) mice. Nat Med 2010; 16: 665-670.
16. Volp K, Brezniceanu ML, Bosser S, Brabletz T, Kirchner T, Gottel D et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 2006; 55: 234-242.
17. Kang HJ, Lee H, Choi HJ, Youn JH, Shin JS, Ahn YH et al. Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers. Lab Invest 2009; 89: 948-959.
18. Salama I, Malone PS, Mihaimeed F, Jones JL. A review of the S100 proteins in cancer. Eur J Surg Oncol 2008; 34: 357-364.
19. Heijmans J, Muncan V, Jacobs RJ, de Jonge-Muller ES, Graven L, Biemond I et al. Intestinal tumorigenesis is not affected by progesterone signaling in rodent models. PLoS ONE 2011; 6: e22620.
20. Constien R, Forde A, Liliensiek B, Grone HJ, Nawroth P, Hammerling G et al. Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis 2001; 30: 36-44.
21. Barker N, van Es JH, Kuipers J, Kujala P, van den BM, Cozijnsen M et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007; 449: 1003-1007.
22. Cole AM, Myant K, Reed KR, Ridgway RA, Athineos D, van den Brink GR et al. Cyclin D2-cyclin-dependent kinase 4/6 is required for efficient proliferation and tumorigenesis following Apc loss. Cancer Res 2010; 70: 8149-8158.
23. Sakaguchi M, Murata H, Yamamoto K, Ono T, Sakaguchi Y, Motoyama A et al. TIRAP, an adaptor protein for TLR2/4, transduces a signal from RAGE phosphorylated upon ligand binding. PLoS ONE 2011; 6: e23132.
24. Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker K et al. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008; 205: 275-285.
25. Heijmans J, Buller NV, Muncan V, van den Brink GR. Role of mast cells in colorectal cancer development, the jury is still out. Biochim Biophys Acta 2010; 1822: 9-13.
26. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.